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Abstract 
Introduction: dysautonomic dysfunction and cognitive impairment represent the most disabling 
non-motor features of Parkinson’s Disease (PD). Recent evidences suggest the association between 
Orthostatic Hypotension (OH) and PD-Dementia. However, little is known on the interactions 
between cardiovascular dysautonomia and Mild Cognitive Impairment (MCI). We aimed to 
evaluate the association between cardiovascular dysautonomia and MCI in patients with PD. 
Methods: non-demented PD patients belonging to the PACOS cohort underwent a comprehensive 
instrumental neurovegetative assessment including the study of both parasympathetic and 
sympathetic function (30:15 ratio, Expiratory-Inspiratory ratio [E-I] and presence of Orthostatic 
Hypotension [OH]). Diagnosis of MCI was made according to the MDS criteria level II.  
Results: we enrolled 185 PD patients of whom 102 (55.1%) were men, mean age was 64.6 ± 9.7 
years, mean disease duration of 5.6 ± 5.5 years with a mean UPDRS-ME score of 31.7 ± 10.9. MCI 
was diagnosed in 79 (42.7%) patients. OH was recorded in 52 (28.1%) patients, altered 30:15 ratio 
was recorded in 39 (24.1%) patients and an altered E-I ratio was found in 24 (19.1%) patients. 
Presence of MCI was associated with an altered 30:15 ratio (adjOR 2.83; 95%CI 1.25-6.40) but not 
with an altered E-I ratio, while OH was associated only with the amnestic MCI subgroup (OR 2.43; 
95% CI 1.05-5.06). 
Conclusion: in our study sample, MCI was mainly associated with parasympathetic dysfunction in 
PD. 
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Introduction 
Dysautonomic dysfunction and cognitive impairment represent the most disabling non-
motor features of Parkinson’s Disease (PD). Cognitive impairment in PD ranges from Mild 
Cognitive Impairment (MCI) to Parkinson’s Disease Dementia (PDD) and it can be present even in 
the early phase of the disease, with up to 30% of the patients presenting MCI at the time of 
diagnosis [1]. 
Recent evidences suggest a possible association between cardiovascular autonomic 
dysfunction and cognitive impairment in PD, and in particular Orthostatic Hypotension (OH) has 
been demonstrated to be associated with PDD [2]. Two mechanisms have been hypothesized in 
order to explain the possible role of OH in the development of cognitive impairment: the influence 
of frequent blood drops on vascular damage to cortical brain areas or the presence of a more 
widespread neurodegeneration characterized by the presence of cognitive impairment and OH [2].  
Nevertheless, the possible relationship between the different components of cardiovascular 
autonomic function and PD-MCI have not been elucidated, except for one study focusing on OH 
that found no association with PD-MCI [3]. 
The main objective of the present study was to evaluate the possible relationship between 
cardiovascular dysautonomia and MCI in a large cohort of PD patients. This study is part of The 
PArkinson’s disease COgnitive impairment Study (PACOS) a study involving two centers located 
in south Italy (Sicily), aimed at evaluating frequency, clinical features and biomarkers associated 
with MCI in a large hospital-based cohort of PD patients [1]. 
 
Materials and methods  
Study population 
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Patients affected by PD were retrospectively selected from the Neurologic Unit of the 
“Policlinico Vittorio Emanuele” in Catania, and the Memory and Parkinson’s Disease Center of the 
“Policlinico Paolo Giaccone” in Palermo, during a 6-year period (2011–2016). 
A sample of 185 PD patients from the original cohort of the PACOS study [1] was included 
in the present study based on the following criteria: a comprehensive neuropsychological and 
neurovegetative assessment to detect cardiac autonomic function. All patients underwent a 
neurological examination including the administration of the Unified Parkinson’s Disease Rating 
Scale (UPDRS), Hoehn and Yahr scale (HY) and a neuropsychological evaluation as detailed 
elsewhere [1,4]. Patients were classified in PD with Normal Cognition (PD-NC) or PD-MCI 
according to the MDS Level II criteria [5]. Furthermore, patients with MCI have been classified in 
amnestic MCI single domain (aMCIsd) and multiple domain (aMCImd) or non-amnestic MCI 
single domain (naMCIsd) and multiple domain (naMCImd). The overall burden of dopaminergic 
drugs was evaluated with the total daily Levodopa Equivalent Dose (LED) [6]. All participants 
provided written informed consent prior to entering the study, which was approved by the local 
medical Ethics Committee and in accordance with the Declaration of Helsinki. 
 
Cardiac autonomic function assessment  
All the evaluations have been performed in fasting patients between 8 am and 9 am. Patients 
in dopaminergic therapy were assessed in their “practical OFF” motor status after an overnight 
washout. Heart rate response to deep breathing tested both afferent and efferent vagal pathways by 
evaluating the maximal heart rate variability (R-R interval) during the manoeuvre. It was expressed 
as the mean Expiratory-Inspiratory (E-I) ratio of the maximal and minimal heart rate obtained in 6 
consecutive respiratory cycles [7]. Heart rate response to standing tested the cardioacceleration 
response to exercise and the subsequent baroreflex-mediated heart rate response by computing the 
30:15 ratio (R-R interval at beat 30 seconds/R-R interval at beat 15 seconds) [7]. Both E-I and 
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30:15 ratio parameters for single subjects were considered abnormal according to age-dependent 
values (DANTEST, Medeia Inc.). Baseline blood pressure has been recorded at least five minutes 
after reaching the supine position. Using an automated sphygmomanometer, three measurements 
with a 1 minute interval have been used to assess the average baseline pressure and, when assuming 
the standing position, at 30, 60, 120 and 180 seconds. The presence of OH was based on the 
detection of a systolic and diastolic blood pressure reduction of at least 20 and 10 mm Hg 
respectively, within 3 minutes of standing [8]. 
 
Statistical analysis 
The data were analyzed using STATA 12.1 software packages. In order to evaluate the 
possible predictors of MCI, an unconditional multivariate logistic regression analysis was 
performed. Parameters associated with the outcome at the univariate analysis with a threshold of p 
= 0.10 were included in the model. Age at baseline and sex were considered as a priori 
confounders. The model was manually constructed using the likelihood ratio test (LRT). Patients 
have been stratified in short disease duration (≤5 years) or long disease duration (>5 years). A 
subgroup analysis has been performed to analyse the association between the neurovegetative tests 
and the different MCI phenotypes. 
 
Results 
From the PACOS cohort consisting of 659 non-demented PD patients, 185 PD patients (102 
men; mean age 64.6 ± 9.7 years) underwent a complete cardiac autonomic function assessment and 
were included in the analysis.  
At the time of the enrolment, PD patients presented a mean disease duration of 5.6 ± 5.5 
years, a mean UPDRS-ME score of 31.7 ± 10.9, a mean HY stage of 2.2 ± 0.7, and a mean LED of 
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355.0 ± 434.0. Among them 27 (14.6%) reported a history of diabetes and 66 (35.7%) a history of 
hypertension (Table 1). 
When stratified according to the 5 years of disease duration 113 patients (61.1%) had a 
disease duration ≤5 years, while 72 (38.9%) had a longer disease duration. Out of the 185 non-
demented PD patients 79 (42.7%) fulfilled the diagnosis of PD-MCI. Concerning the MCI subtype, 
the majority had multidomain MCI (39 [49.4%] were naMCImd and 25 [31.6%] aMCImd), while 
only few presented a single domain MCI (10 [12.7 %] were naMCIsd and 5 [6.3 %] aMCIsd). 
Prevalence of MCI in this sample was close to that recorded in the entire PACOS cohort (39.6%) 
[1]. 
Regarding cardiac autonomic parameters, OH was recorded in 52 (28.1%) patients, being 
significantly more frequent in patients with long disease duration versus those with a short duration 
(59.6% and 40.4%, respectively; p<0.001). Altered 30:15 ratio was recorded in 39 (24.1%) patients, 
with no significant difference between short versus long disease duration (29.5% and 21.0% 
respectively). An altered E-I ratio was found in 24 patients (19.1%), without any significant 
difference between short versus long disease duration (18.8% and 19.6% respectively).  
At univariate analysis, the presence of MCI was significantly and positively associated with 
male sex, disease duration, age, age at onset, and 30:15 ratio test, while a significant negative 
association was found with educational level (Table 2). After multivariate analysis, adjusting by 
sex, age, disease duration and education, the presence of altered 30:15 ratio was associated with an 
almost three times increased risk of MCI (adj OR 2.83; 95%CI 1.25-6.40; p-value 0.01) as shown in 
table 2. Frequency of altered 30:15 ratio was not significantly different among patients with and 
without OH (33.3% vs 20.5% respectively; p = 0.09). Similar results were obtained when analysis 
has been conducted excluding patients with diabetes and hypertension, as well as when both 
diabetes and hypertension were included in the multivariate model. 
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When patients were divided according to an amnestic or a non amnestic MCI phenotype, 49 
(62.0%) patients were classified as naMCI, while 30 (38%) had aMCI. Demographic characteristics 
of the two groups were comparable except for a slightly higher prevalence of men (86.7% versus 
53.1%) in the aMCI group. At the univariate analysis an altered 30:15 and the presence of OH were 
significantly associated with aMCI with, respectively an OR of 3.49 (95% CI 1.36-8.94; p=0.009) 
and an OR of 2.43 (95% CI 1.05-5.06; p=0.037). 
 
Discussion  
The nature and the pathophysiological processes leading patients with PD to develop 
cognitive impairment are still unclear. Recently, a great effort has been spent in investigating 
potential biomarkers that may allow to stratify PD patients according to their risk of progressing to 
dementia, because of the increased disease burden and possible treatment strategies. Among 
evaluated biomarkers, the presence of MCI represents one of the strongest predictor of a future 
development of dementia [9]. Furthermore, there is a growing body of evidence that associates the 
presence of cardiovascular dysautonomia, especially OH, with cognitive impairment and dementia 
[2,10]. However, cardiovascular dysautonomia may be present even in the earliest phases of PD, 
involving the parasympathetic function with [11] or without [12] concurrent sympathetic 
dysfunction. 
At multivariate analysis we found an association between a test that assesses the 
cardiovascular parasympathetic function (30:15 ratio) and PD-MCI (OR 2.83). Differently from 
data reported on PDD, OH was not associated with PD-MCI in the whole sample, but a significant 
association was found only when analysis was restricted to aMCI. 
Based on available literature, only another study has evaluated the association between OH 
and PD-MCI, finding also no association [3]. Our results are in agreement with this report even if 
8 
 
different methodologies have been used. In this previous study, in fact, the researchers tested only 
OH and supine hypertension and applied a broader definition of MCI, while in our study autonomic 
function has been investigated by a set of standardized neurophysiological measurements and the 
diagnosis of MCI has been made according to MDS criteria Level II. 
Even if we have not a clear explanation for the restricted association between OH and the 
subgroup of aMCI, it could be hypothesized that aMCI and PDD may share the same pathological 
background as compared to naMCI. Some studies have suggested a high risk of progression from 
aMCI to PDD with respect to naMCI, but literature data are still controversial [13]. 
To the best of our knowledge, this is the first study that has evaluated the association 
between cardiovascular autonomic functions and PD-MCI. The presence of an altered 
parasympathetic function in MCI has been already described in subjects with MCI due to 
Alzheimer’s Disease [14]. In these patients, it has been in fact suggested that reduced acetylcholine 
levels may affect both cognitive function and parasympathetic nervous system whose main 
neurotransmitter is represented by acetylcholine [14].  There is still uncertainty in literature 
regarding the role of cholinergic neurons in PD patients brain [15]. However it has been 
demonstrated that progressive degeneration of structures such as the nucleus basalis of Meynert and 
the dorsal motor nucleus of the vagus, the former implicated in cognitive performances and the 
latter in parasympathetic function, are part of the pathological processes underlying PD. According 
to Braak’s hypothesis, both these structures may be involved in the pathologic distribution of alpha-
synuclein pathology, impairing the cholinergic projections that regulate cognition and autonomic 
function at different disease stages [16]. 
   We are aware that some limits should be taken into account in interpreting our data. Due to 
the hospital-based design a possible selection bias cannot entirely ruled out. Indeed the possibility 
of more severe cases attending the two hospital centers involved in the study cannot be excluded, 
even if baseline characteristics of the PACOS cohort are comparable with the majority of published 
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studies [1,17].  Furthermore, concerning the neurovegetative assessment, we are aware that the 
restricted number of parameters evaluated (only two tests that primarily assess the parasympathetic 
function and just one for the sympathetic function) could limit the accuracy of our findings, thus 
caution must be taken in speculating the type of cardiovascular autonomic dysfunction found in PD-
MCI.  Moreover the interpretation of obtained results is limited by the cross-sectional study design, 
which does not allow to assess any kind of causal relationship, but only the presence of 
associations. Accordingly, prospective studies are needed in order to evaluate the progression of 
MCI and cardiovascular dysautonomia in PD patients. 
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    Table 1: demographic and clinical characteristics of the study sample 
 
 PD-NC 
N= 106 
PD-MCI 
N = 79 
Total 
N=185 
Sex, Men (%) 50 (47.2)      52 (65.8)      102 (55.1)      
Age (mean ± SD) 63.6 ± 10.6         66.0 ±  8.1         64.6 ± 9.7         
Age at onset (mean ± SD) 58.7 ± 10.5         59.4 ± 10.3         59.0 ± 10.4        
Disease duration, years (mean ± SD) 4.9 ±  4.9          6.5 ± 6.1          5.6  ±  5.5          
Educational level (mean ± SD) 10.7 ± 4.4          8.3 ± 4.7          9.6 ± 4.7          
UPDRS-ME (mean ± SD) 30.4 ± 10.5         33.4 ± 11.4        31.7 ± 10.9         
Hoehn and Yahr Score (mean ± SD) 2.2 ± 0.6          2.3 ± 0.7          2.2 ±  0.7 
LED (mean ± SD) 293.9 ± 393.4          436.2 ± 473.1          355.0 ± 434.0 
MMSE (mean ± SD) 27.7 ± 1.9       26.8 ± 1.8       27.3  ± 1.9 
Diabetes 11 (10.4) 16 (20.2) 27 (14.6) 
Hypertension 38 (35.9) 28 (35.4) 66 (35.7) 
Cardiac autonomic functions    
OH 28(26.4)       24(30.4)      52(28.1)       
E-I 16(19.7)       8(17.8)       24(19.0)       
30:15 18(18.4)       21(32.8)       39 (24.1)      
 
Abbreviations: PD-NC, Parkinson’s Disease with normal cognition; MCI, Mild Cognitive 
Impairment; UPDRS-ME, Unified Parkinson’s Disease Rating Scale, Motor Examination; 
LED, Levodopa Equivalent Daily Dose; MMSE, Mini-Mental State Examination; OH, 
Orthostatic hypotension; E-I, Expiratory-Inspiratory ratio. 
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Table 2. Univariate and multivariate analysis. 
 Univariate analysis  Multivariate analysis  
 OR 95%CI p-value AdjORs 95%CI p-value 
Sex, men 2.15 1.18-3.93 0.01 3.47 1.63-6.40 0.001 
Age* 1.02 0.99-1.05 0.1 1.01 0.98-1.05 0.3 
Age at onset* 1.00 0.98-1.03 0.7 / / / 
Disease duration* 1.05 1.00-1.11 0.05 1.04 0.97-1.11 0.3 
Educational level* 0.89 0.83-0.95 0.001 0.84 0.77-0.92 <0.0001 
UPDRS-ME ≤ 20 (median) 1.05 1.00-1.05 0.07 / / / 
Hoehn-Yahr Score 1.34 0.85-1.06 0.2 / / / 
LED* 1.00 1.00-1.001 0.03 / / / 
Cardiac autonomic functions 
     
 
OH 1.21 0.64-2.31 0.5 / / / 
E-I 0.89 0.34-2.25 0.8 / / / 
30:15 2.17 1.04-4.50 0.04 2.83 1.25-6.40 0.01 
 
 
Abbreviations:  *continuous variables; AdjORs = ORs have been adjusted by sex, age, education 
considered as a priori confounders; UPDRS-ME, Unified Parkinson’s Disease Rating Scale 
Motor Examination; LED, Levodopa Equivalent Daily Dose; OH, Orthostatic hypotension; E-I, 
Expiratory-Inspiratory ratio. 
  
 
 
 
 
 
 
• MCI seems to be associated with cardiovascular autonomic dysfunction in PD. 
• OH is present in almost one third of PD patients 
• OH is more frequent in patients with amnestic MCI 
